Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck
复制标题
DOI：
10.1158/1078-0432.ccr-04-2029
复制
发表时间：
2005-04-15
影响因子：
11.5
通讯作者：
Lee, SH
中科院分区：
文献类型：
--
作者：
Lee, JW;Soung, YH;Lee, SH
目的：近年来，在非小细胞肺癌中发现了表皮生长因子受体（EGFR）基因的激酶结构域突变，这些突变与酪氨酸激酶抑制剂吉非替尼的临床反应有关。吉非替尼治疗在头颈部鳞状细胞癌（SCCHN）中也显示出临床益处，本研究的目的是探讨SCCHN携带EGFR突变的可能性。实验设计：本研究对41例SCCHN的EGFR基因进行pcr -单链构象多态性分析，检测体细胞突变。结果：总的来说，我们检测到3个EGFR突变（7.3%），所有突变都是在第19外显子（E746_A750del）相同的框内缺失突变。结论：这些数据表明，除非小细胞肺癌外，SCCHN还存在EGFR基因突变，提示吉非尼替临床适用于SCCHN患者的基本原理。
Purpose: Recently, the kinase domain mutations of epidermal growth factor receptor (EGFR) gene have been identified in non -small-cell lung cancer, and these mutations have been related to the clinical response to the tyrosine kinase inhibitor gefitinib. Gefitinib treatment has also shown clinical benefits in squamous cell carcinoma of the head and neck (SCCHN), The aim of this study was to explore the possibility that SCCHN harbored the EGFR mutations.Experimental Design: In this study, we analyzed EGFR gene in 41 SCCHN for the detection of the somatic mutations by PCR-single-strand conformational polymorphism analysis.Results: Overall, we detected three EGFR mutations (7.3%), and all of the mutations were the same in-frame deletion mutation in exon 19 (E746_A750del).Conclusion: These data indicated that in addition to non -small-cell lung cancer, SCCHN harbors the EGFR gene mutations, and suggested the rationale for the clinical applicability of gefinitib to SCCHN patients.